Stratec SE

STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
  • TickerSBS
  • ISINDE000STRA555
  • SectorHealth Care Equipment & Services
  • CountryGermany

STRATEC BIOMEDICAL AG suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of STRATEC BIOMEDICAL AG (DE), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date November 10, 2020, the closing price was EUR 101.60 and its target price was es...

Stratec - Strong sales growth helped by COVID-19

Stratec SE is a highly regarded German company that designs, develops and supplies about 8,000 fully automated diagnostics systems and modules annually. Clients include major companies like Hologic, DiaSorin and Siemens Healthineers. Typical 12–15-year product life cycles give underlying stability. Stratec is benefiting from COVID-19 driven diagnostic demand. H120 sales were €119.4m, up 9.9% y-o-y, with a 15.4% adjusted EBIT margin. The company guides to FY20 revenue growth of 14–18% with a 15.5–16.5% adjusted EBIT margin.

Alexander Rummler ...
  • Manuel Martin, CEFA,CREA

ODDO BHF GERMAN MORNING NEWS – DETAILED COMMENTS 08.15.2018

...

STRATEC Biomedical AG : Downgrade to Reduce after weak H1 results and revised outlook for 2018

>Weak H1 2018 results miss our estimates - Stratec published H1 18 results. Consolidated sales fell 10.5% (nominally) to € 90.2m (Oddo BHFe: € 96.1m; H1 2017: € 51.2m). Organically, sales declined 3.9% yoy. Note that the nominal sales decline of 10.5% includes exchange rate effects and the first-time adoption of IFRS 15 each of each negatively impacted sales growth by 3.3pp.H1 2018 adj. EBIT fell 31% yoy to € 8.9m (Oddo BHFe: € 11.2m, H1 2017: € 12.8m). The adj. ...

Update: Excellent strategic fit with integrated consumables

Stratec, a designer and builder of automated OEM diagnostic systems, has announced its intention to acquire an Austrian business that designs and manufactures complex precision consumables for high-end biomedical and diagnostic systems. This is an excellent strategic fit as it will allow Stratec to integrate high-value consumables into system designs and accumulate recurring revenues: Stratec expects a 20% CAGR to 2020 on DADC 2015 sales of €17m. Stratec is experiencing reduced Chinese orders and the guided 5% EBIT of DADC may lower the 2017 EBIT margin to 17%.

Update: Hungary Haematology offsets Chinese famine

Stratec, a German designer and builder of automated OEM diagnostic systems, has revised its core business guidance for 2016 and 2017 due to volatile client forecasts arising from sales uncertainty and local competition in China. Preliminary 2015 results showed revenues up 1.4% to €146.9m and an improved EBIT margin of 18.3% due to higher service part sales. The about €67m Diatron acquisition adds about €25m revenue in FY16 and €37m in FY17, taking our 2016 consolidated revenue forecast to a revised €176m, with 2017 revenues potentially at €198m. Diatron’s EBIT margin is assumed t...

STRATEC BIOMEDICAL AG suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of STRATEC BIOMEDICAL AG (DE), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date November 10, 2020, the closing price was EUR 101.60 and its target price was es...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch